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The development of an alternative source for donor lungs would change the paradigm of lung
transplantation. Recent studies have demonstrated the potential feasibility of using decellularized
lungs as scaffolds for lung tissue regeneration and subsequent implantation. However, finding a
reliable cell source and the ability to scale up for recellularization of the lung scaffold still remain
significant challenges. To explore the possibility of regeneration of human lung tissue from stem
cells in vitro, populations of lung progenitor cells were generated from human iPSCs. To explore
the feasibility of producing engineered lungs from stem cells, we repopulated decellularized
human lung and rat lungs with iPSC‐derived epithelial progenitor cells. The iPSCs‐derived epithe-
lial progenitor cells lined the decellularized human lung and expressed most of the epithelial
markers when were cultured in a lung bioreactor system. In decellularized rat lungs, these
human‐derived cells attach and proliferate in a manner similar to what was observed in the
decellularized human lung. Our results suggest that repopulation of lung matrix with iPSC‐derived
lung epithelial cells may be a viable strategy for human lung regeneration and represents an
important early step toward translation of this technology.
KEYWORDS
decellularized lung, epithelial cells, induced pluripotent stem cell (iPSC), lung implant, tissue
regeneration bioreactor1 | INTRODUCTION
Engineered lungs made using decellularized allogeneic or xenogeneic
lungs and repopulated with patient‐specific cells may be a future
option for the replacement of diseased lungs (Badylak, Weiss, Caplan,
& Macchiarini, 2012; McCurry et al., 2009; Price, England, Matson,
Blazar, & Panoskaltsis‐Mortari, 2010; Song & Ott, 2011; Tesei et al.,
2009; Wagner et al., 2013). Lung tissues that provide gas exchange
have been generated from decellularized scaffolds and primary epithe-
lial cells and successfully transplanted into small animal models for
periods of a few hours (Ott et al., 2010; Petersen et al., 2010).
A key hurdle for the reconstruction of human lung tissue is the lack
of an abundant source of human lung epithelial cells (Brouwer,
Hoogenkamp, Daamen & van Kuppevelt, 2013; Gilpin, Charest, Ren, &
Ott, 2016; Petersen, Calle, &Niklason, 2011; Rana, Anson, Engle, &Will,wileyonlinelibrary.com/2012;Wagner et al., 2013). Primary cells isolated from patients can rap-
idly lose phenotypic marker expression in vitro, and isolation of large
numbers of cells for expansion is difficult and costly. This may limit
the application of these primary cells for lung tissue engineering.Human
induced pluripotent stem cells (iPSCs) are a potentially attractive source
for the generation of lung epithelial cells, though differentiation para-
digms remain at an early stage in this field (Brouwer et al., 2013; Kotton,
2012; Takahashi et al., 2007). Despite ongoing challenges, the key
advantage of using autologous iPSCs is the potential to avoid immune
rejection (Beers et al., 2017; Kubo, 2012; Nishikawa, Goldstein, &
Nierras, 2008; Takahashi et al., 2007; Yu et al., 2007). In addition, the
iPSC‐derived cells can perhaps expand to necessary numbers—that is,
many billions—to repopulate decellularized human‐sized lung scaffolds.
We have previously reported a stepwise differentiation protocol
to generate a population of type II epithelial‐like progenitor cells fromCopyright © 2017 John Wiley & Sons, Ltd.journal/term e1623
e1624 GHAEDI ET AL.human iPSCs (Ghaedi et al., 2013). The type II progenitor cells
derived from iPSC were positive for markers (prosurfactant proteins)
such as pro‐SPC and pro‐SPB. In this study, we adapted the
differentiation protocol to generate airway progenitor cells from iPSC,
based upon recently reported methods with a few modifications
(Huang et al., 2014; Longmire et al., 2012; Mou et al., 2012; Wang,
Haviland, Burns, Zsigmond, & Wetsel, 2007). The next goal, was to
explore the capacity of iPSC‐derived lung progenitor cells to repopu-
late a decellularized lung scaffold and evaluate cell viability and
phenotype of these cells while they were cultured on decellularized
lung scaffold.
To determine the feasibility of producing repopulated lungs from
iPSC‐derived epithelial stem cells, we repopulated decellularized
human lung obtained from tissues not suitable for transplantation.
The acellular scaffolds were repopulated in the alveolar and airway
compartment with iPSC‐derived lung progenitor cells, and we assessed
the cell attachment, viability, and epithelial phenotype retention on the
human scaffolds.
We further generated the engineered rat lung from both endothelial
cells and iPSC‐derived epithelial cells in a rat bioreactor system (Gilpin,
Charest, Ren, Tapias, et al., 2016; Petersen et al., 2010; Petersen, Calle,
Colehour, & Niklason, 2011). The iPSC‐lung epithelial cells and rat lung
microvascular endothelial cells were introduced to the airway and vas-
cular compartments of acellular rat scaffolds, respectively, and were
cultured for 3–5 days in a bioreactor system.
Our study makes further progress in the field of lung tissue engi-
neering, by evaluating the potential suitability of iPSC‐derived cells
to repopulate clinically applicable matrices. In addition, this technology
may provide an ex vivo model for the deeper understanding of human
lung biology and lung disease and for studying the interactions
between progenitor cells and lung scaffolds.2 | MATERIALS AND METHODS
2.1 | Cultivation of human iPSCs
The two human episomal iPSC lines (MIRJT7i‐mND2‐0 and iPS‐DF6‐
9‐9 T.B) utilized in this study were provided by Prof. James A. Thom-
son, Department of Anatomy, University of Wisconsin‐Madison, Mad-
ison, WI, USA. Both human iPSC lines were propagated on Matrigel in
mTesR medium, with medium changes every day. Undifferentiated
iPSCs were passaged onto fresh Matrigel every 4–5 days.
2.2 | In vitro differentiation of iPSCs into alveolar
and airway epithelial cells
The iPSCs were first differentiated toward definitive endoderm (DE)
in RPMI 1640 medium supplemented with 100‐ng/ml activin A,
2‐mM L‐glutamine, and 1% antibiotic‐antimycotic for 48 hr. Then,
1xB27 supplement and 0.5‐mM sodium butyrate were added into the
same medium, and cells were cultured in this medium for 3 days
(D'Amour et al., 2005; Duan et al., 2010). Subsequently, the DE cells
were trypsinized and replated on human extracellular matrix protein
(Sigma Aldrich)‐coated plates and were differentiated to anterior
foregut endoderm (AFE) cells by exposing them sequentially todorsomorphin/SB431542 from days 5 to 6, followed by IWP2 /
SB431542 from days 6 to 7 (Figure S2) in Iscove's Modified Dulbecco's
Medium with 10% fetal bovine serum, 2‐mM L‐glutamine, 1‐mM non-
essential amino acids, 1% antibiotic‐antimycotic (Green et al., 2011;
Huang et al., 2014; Mou et al., 2012).
The AFE cells were maintained in lung endoderm differentiation
medium consisting of Iscove's Modified Dulbecco's Medium and F12
(3:1) with 10% fetal bovine serum, 2‐mM L‐glutamine, 1‐mM nonessen-
tial amino acids, 1% antibiotic‐antimycotic, 1X B27, 1X N2 supple-
ment, ascorbic acid (50 μg; basal medium), supplemented with
retinoic acid (0.5 μM), bFGF (10 ng/ml), BMP4 (10 ng/ml), CHIR99021
(3 μM/ml), and keratinocyte growth factor (KGF; 10 ng/ml each) for
7 days (Huang et al., 2014; Longmire et al., 2012).
To differentiate the early lung progenitor cells to the ATII (type II
epithelial) progenitor cells, they were cultured in the same basal media
describe above supplemented with fibroblast growth factor 10
(FGF10; 10 ng/ml), retinoic acid (0.5 μM), epidermal growth factor
(EGF; 10 ng/ml), CHIR99021 (3 μM/ml), and KGF (10 ng/ml) for
another 10 days. At day 25, the growth factor combination was
switched to retinoic acid (0.5 μM), EGF (10 ng/ml), FGF10 (10 ng/ml),
and KGF (10 ng/ml) dexamethasone (50 nM), butyryl cGMP (0.1 mM),
and isobutylmethylxanthine (0.1 mM) and cells were cultured in this
medium, until use (Green et al., 2011; Longmire et al., 2012).
To differentiate the early lung progenitor cells to the proximal air-
way progenitor cells, at day 15, the growth factors combination was
switched to high concentration of retinoic acid (1 μM), RA‐supple-
mented B27, BMP7 (10 ng/ml), KGF (10 ng/ml), EGF (10 ng/ml), dexa-
methasone (50 nM), butyryl cGMP (0.1 mM), and
isobutylmethylxanthine (0.1 mM) for 15 days. (Huang et al., 2014;
Mou et al., 2012; see detailed protocols in Supporting Information).
Following culture protocol for human airway described by Randell's
laboratory (Fulcher & Randell, 2013), on day 32, cells were split with
trypsin and reseeded on collagen I/III‐coated plates in BEGM™
medium from Lonza until use (Fulcher & Randell, 2013).2.3 | Primary human airway epithelial cells
Human airway epithelial cells procured under the University of North
Carolina at Chapel Hill Institutional Review Board protocol number
03‐1396 were kindly provided by Dr. Scott Randell.2.4 | Preparation of decellularized extracellular
matrix scaffolds
All animal experiments were performed with the approval of the
Institutional Animal Care and Use Committee of Yale University, and
all studies using human lung tissue were approved by the University
of Michigan. Sprague Dawley were used as a source for rat donor
lungs. Human lungs were obtained from beating‐heart donors or warm
autopsy as arranged through Gift of Life Michigan. In order to build a
“protocol” that could be used for rat, and human lungs with
different sizes, we used a decellularization regimen that normalizes to
tissue size and operates on a volume of reagent per gram wet
weight tissue basis as previously described (Balestrini et al., 2015;
Booth et al., 2012).
GHAEDI ET AL. e1625Briefly, decellularization was achieved by perfusion with a
0.0035% Triton X‐100 solution followed by sodium deoxycholate solu-
tions of increasing concentration from 0.01% to 0.1%. The lung was
rinsed with sterile phosphate‐buffered saline (PBS) and perfused with
30‐U/ml Benzonase Nuclease in 1‐M Tris‐buffer with 1‐mM MgCl2.
Lastly, the lobe was rinsed with 0.5% Triton X‐100 solution followed
by additional sterile PBS. (See detailed protocols in Supporting
Information).2.5 | Culture of iPSC‐lung epithelial cells onto lung
extracellular matrix scaffolds
a. Human lung scaffold: Donated human lungs that are not suitable
for transplantation were used to produce natural lung scaffolds
(Booth et al., 2012). The middle‐right lobe of a decellularized
human lung was mounted in the bioreactor. Five hundred million
iPSC‐ATII progenitor cells and 500 × 106 iPSC‐airway progenitor
cells were suspended in 3 ml of epithelial medium and introduced
into the scaffold via the airway. Vascular perfusion with epithelial
growth media was initiated at 3 ml/min immediately after cell
seeding. The reseeded lung scaffolds were then cultured in the
lung bioreactor with no breathing for 4 days in epithelial cell
medium described in Figure S7G (see Supporting Information)
with the whole volume of culture medium (500 ml) changed every
day.
b. Rat lung scaffold: 100 million rat microvascular endothelial cells
(RLMEC) were perfused through the vasculature by gravity‐
driven, pulsatile perfusion, and the lungs were perfused at 1 ml/
min for 4 hr until epithelial cell seeding. Each set of EC‐seeded
lungs were repopulated with 50 million iPS‐epithelial cells
(25 × 106 iPSC‐ATII progenitor cells and 25 × 106 iPSC‐airway
progenitor cells) suspended in 1.5 ml of via the trachea in the bio-
reactor and were perfused between 1 and 4.5 ml/min. The
engineered rat lungs were maintained in a bioreactor system for
4 days in coculture medium described in Figure S7G, with culture
media, changes twice daily (see detailed protocols in Supporting
Information).2.6 | Real‐time quantitative reverse transcription‐
PCR
Total RNA was extracted from cells using the RNeasy Mini Kit from
Qiagen following the manufacturer's instructions. First‐strand comple-
mentary DNA (cDNA) was synthesized using SuperScript First‐Strand
Synthesis System according to manufacturer's protocol (Invitrogen).
Reactions were performed in a 25‐μL volume with iQ™ SYBR Green
Supermix (Bio‐Rad), 1‐μL of cDNA, and 200 nM each of forward and
reverse primers using iCyler and iQ software. Average of Ct values
from the triplicate PCR reactions for a gene of interest were normal-
ized against the average Ct values for glyceraldehyde‐3‐phosphate
dehydrogenase from the same cDNA sample and expressed relative
to normal cadaveric human or rat lung tissue.2.7 | Immunofluorescence, immunohistochemistry,
and flow cytometry
Tissues were fixed in formalin for 4 hr and cells were fixed in 4% para-
formaldehyde for 20 min. For immunofluorescence, fixed cells or tissue
sections after deparaffinization were permeabilized with 0.1% Triton
X‐100 in PBS for 15 min, blocked in 3% BSA in PBS for 60 min at
RT, and then incubated in primary antibody overnight at 4 °C and
secondary antibody for 2 hr at RT. After washing with PBS, the cells
were incubated with DAPI (1 μl/ml) for 1 min and mounted with
PVA‐DABCO cover slipping solution and slides.
For flow cytometry, 5 × 105 cells were resuspended in 250 μl of
fixation/permeabilization solution from a BD Bioscience cytofix/
cytoperm kit for 20 min. After blocking for 30 min on ice, the cells were
incubated with corresponding primary antibody in the blocking solu-
tion for 30 min on ice. The cells were resuspended in 350 μl of
Perm/Wash buffer after incubation with the corresponding conjugated
secondary for 30 min on ice, washed twice, and analysed by flow
cytometry.2.8 | Statistical analyses
All statistical analyses were done with the software Origin (OriginLab,
Northampton, MA). The data were expressed as mean ± standard error
of measurement. The t tests were performed to evaluate whether two
groups were significantly different from each other. The p values less
than .05 (two‐tailed) were considered statistically significant.
Complete methods can be found in the Supporting Information.3 | RESULTS
3.1 | Generation of human lung epithelial cells from
iPSCs
We previously reported a stepwise differentiation method to generate
DE, AFE, and subsequently, early lung progenitor cells from human
iPSCs (Ghaedi et al., 2013). To improve lung epithelial cell phenotype,
in this work, we modified previously published protocols (Green
et al., 2011; Longmire et al., 2012; Mou et al., 2012; Wong et al.,
2012) and generated a protocol to derive both alveolar and airway
progenitor cells from iPSCs, by following the timing and coordination
of the signalling pathways in lung development (Figure 1a).
As in previously published studies (Green et al., 2011; Kubo et al.,
2004), >85% endodermal cells were generated from human iPSCs by
exposing them to saturating concentrations of activin A during the first
5 days of differentiation (Figures 1c,h and S1). In the second step, we
differentiated the DE to AFE by exposing them sequentially between
days 5 and 7 to combinations of the small molecule inhibitors.
(Figures 1a,d,i and S2A‐D; Huang et al., 2014). To specify lung cell fate,
at day 8, the medium was switched to lung endoderm differentiation
medium containing bFGF, BMP4, CHIR, and KGF for 7 days
(Figures S2A and S3). When we examined the expression of the early
lung marker NKX2.1 at day 15 of differentiation, immunostaining and
quantitative PCR results showed that up to 30%–40% of cells were







FIGURE 1 Generation of lung epithelial cells from human induced pluripotent stem cell (iPSC) in vitro. (a) Schematic for differentiation protocol of
human iPSC to alveolar and airway progenitor cells in vitro. (b) Phase‐contrast images of human iPSC, (c) definitive endoderm (DE), (d) anterior
foregut endoderm (AFE), (e) early lung progenitor cells at day 20, (f‐g) alveolar and airway progenitor cells at day 40 (scale bar = 6.3 μm applies to
panels b‐g). (h‐j) immunofluorescent images of differentiated cells from iPSC for (h) SOX17 (endoderm marker) at day 6, (i) PAX9 (anterior foregut
endodermmarker) at day 8 and NKX2.1, early marker of lung progenitor cells at day 20 (scale bar = 31 μm applies to panels h‐i and 21 μm to panel j).
DAPI = 4′,6‐diamidino‐2‐phenylindole; EGF = epidermal growth factor; KGF = keratinocyte growth factor; FGF10 = fibroblast growth factor 10
e1626 GHAEDI ET AL.To differentiate early lung progenitor cells into type II progenitor‐
like cells, we cultured the progenitor cells at day 15 in differentiation
media containing KGF, FGF10, RA, CHIR, EGF for another 2 weeks
(Huang et al., 2014), after which CHIR was removed from the differen-
tiation cocktail for the rest of differentiation (Figure S3). At day 40 of
differentiation, the cells, now termed “ATII progenitor cells,” shown
to express type II cell markers (Longmire et al., 2012; Figures 1f and
S7). Immunofluorescence staining and quantitative reverse transcrip-
tion‐PCR (qRT‐PCR) showed the iPSC‐ATII progenitor cells were posi-
tive for type II markers, including surfactant protein C (SPC) and
NKX2.1, and that a small fraction of the cells expressed type I surface
markers, T1α (Figure 2A‐E).To enhance the differentiation of lung progenitors into a pheno-
type more consistent with airway progenitor cells (i.e., NKX2.1+/P63+
or NKX2.1+/CK5+) rather than ATII progenitor cells, at day 15, the
growth factor combination was switched to BMP7, KGF, high‐concen-
tration retinoic acid, and WNT antagonist (IWR‐1). After 17 days, the
medium was switched to BEGM from Lonza (Mou et al., 2012; Figures
S2A and S3). Immunostaining at day 40 showed cells now termed “air-
way progenitor cells” (Figure 1g), stained positive for several airway
progenitor cell markers such as NKX2.1, P63, CK5, and CK14
(Figure 2f‐i). Furthermore, quantitative RT‐PCR revealed that CK5
and P63 were expressed in iPSC‐airway progenitor cells (up to 50%









FIGURE 2 Generation of lung alveolar and airway epithelial progenitor cells from human induced pluripotent stem cell (iPSC) in vitro. (a‐d)
immunofluorescent images of iPSC‐alveolar progenitor cells at day 40 (cytocentrifuged prepared), illustrating positive staining for (a) 4′,6‐
diamidino‐2‐phenylindole (DAPI), (b) DAPI‐SPC, (c) DAPI, and (d) DAPI‐NKX2.1. (e) Quantitative reverse transcription‐PCR (qRT‐PCR) analysis of
type II epithelial cell markers in iPSC‐lung progenitor cells at day 40; surfactant proteins B and C, and T1α (a type I cell marker). (f‐i)
immunofluorescent staining for airway markers in iPSC‐airway progenitor cells (cytocentrifuged prepared) at day 40: (f) DAPI‐P63, (g) NKX2.1 and
P63, (h) DAPI‐CK14, (i) DAPI‐CK5 (scale bar = 31 μm applies to panels a‐d and f‐i). (j) qRT‐PCR analysis of airway epithelial cell markers in iPSC‐lung
progenitor cells at day 40. For qRT‐PCR, values from three independent experiments from the triplicate PCR reaction for each gene were
normalized to average glyceraldehyde‐3‐phosphate dehydrogenase Ct values from the same cDNA samples. The relative expression of each gene
was then calculated to normal human lung (hlung) and airway cells isolated from human trachea (hAEC; n = 3 independent replicates for qRT‐PCR,
error bars indicate ± SEM and *indicates p < .05 and ns indicates no significant difference). CCSP = Clara cell secretory protein; CFTR = cystic
fibrosis transmembrane conductance regulator; hAEC = human airway epithelial cells
GHAEDI ET AL. e1627
e1628 GHAEDI ET AL.epithelial markers as compared with freshly isolated human airway
cells and human lung RNA (Figure 1j).
Together, these results indicated differentiation of human iPSC
cells into lung epithelial progenitor cells expressing main alveolar and
airway markers such as SPC, NKX2.1, P63, and CK5. Given these
observations, we elected to determine the fate of these cells when
seeded into acellular lung scaffolds (Gomperts & Strieter, 2007;
Rackley & Stripp, 2012; Rock et al., 2011).3.2 | Repopulating human lung tissue scaffolds with
iPSC–lung epithelial cells
Next, we explored the capacity of iPSC‐derived lung progenitor cells to
repopulate the airway compartment of a decellularized lung ECM.
Acellular middle right lobes of the human lung were reseeded with
an iPSC‐ATII progenitor cells and iPSC‐airway progenitor cells. In
repopulated constructs, cell coverage was assessed by histological
staining of multiple sections. haematoxylin and eosin staining showed
that iPSC‐derived epithelial cells were able to diffusely repopulate
alveolar structures and conducting airways within the intact lung scaf-
fold (Figure 3b‐c). To engineer a functional lung repopulating a native
lung matrix with sufficient cell numbers in appropriate anatomic loca-
tions is required (Gilpin, Charest, Ren, & Ott, 2016; Gilpin, Charest,
Ren, Tapias, et al., 2016). Immunostaining showed some cells in the
alveolar compartments of the repopulated lung expressed the type II
cell markers, SPC, and NKX2.1, and cellular expression of these
markers was robust at day 4 of culture (Figure 3f‐k). We also observed
that cells located in the airway compartments were positive for airway
epithelial markers such as Clara cell secretory protein (CCSP) and
Forkhead box protein J1 (FOXJ1), confirming the commitment of the
iPSC‐airway progenitor cells to airway phenotype after scaffold culture
(Figure 3l‐q). However, the cell attachments were not site specific and
in some sections of the repopulated lung, cells which landed in alveolar
compartment expressed airway markers or cells that landed in airway
compartments expressed alveolar cells markers. The iPSC‐derived epi-
thelial cells used for repopulating the acellular lung scaffold are still
progenitor cells at the time of seeding. Long‐term culture, in bioreactor
system, might help these cells to differentiate into the right cell type
based on the signals that they receive from the scaffold or growth
media. Immunostaining for proliferating cell nuclear antigen and cas-
pase‐3 (apoptotic marker) showed that the cells were able to replicate
in the acellular scaffold and displayed few markers of apoptotic cell
death during the culture period. This confirmed that our bioreactor cul-
ture system successfully maintained adequate nutrient transfer for the
ex vivo repopulated lungs and facilitated the continued growth and
expansion of the iPSC‐derived progenitor cells (Figure 4a,b)
To quantify the expression of cell markers the repopulated human
lung tissues were assayed by qRT‐PCR for expression levels of various
epithelial markers and compared with mRNA derived from native
human lung. We identified a trend for higher expression of lung epithe-
lial markers such as SPC, T1α, CK5, and Mucin 5 AC in iPSC‐derived
lung progenitor cells cultured in the lung scaffold, compared with the
same cells grown on traditional culture plates. The expression of
FOXJ1 and P63 was significantly higher in cells cultured in the lung
scaffold compared with the same cells cultured on tissue culture plate.These data suggest that the 3D acellular lung and the physiological rel-
evant culture system improved the differentiation and maturation of
the iPSC‐derived cells (Figure 4c). However, in most cases, levels of
epithelial gene expression in the engineered lung were significantly
lower than those in native lung samples.3.3 | Engineered rat lung from human iPSC‐lung
epithelial cells and rat microvascular endothelial cells
To generate the lung tissue from both epithelial and endothelial cells,
RLMEC were delivered into the vascular compartment of the
decellularized rat lung. Subsequently, ATII and airway progenitor cells
from human iPSC were introduced via the airways to repopulate the
alveolar and airway compartment of the scaffold.
When the cell coverage and proliferative capacity of the cells
within the matrix were assessed, haematoxylin and eosin staining
showed that RLMEC and iPSC‐derived cells were able to repopulate
alveolar‐airway lung structures and vascular compartment within the
scaffold (Figure 5a,b). Immunofluorescence showed epithelial cells
present in the alveolar compartments expressed alveolar type II
markers, SPC, SPB, and NKX2.1 (Figure 5c‐e) while cells within the air-
way compartments expressed airway markers, CCSP, FOXJ1, and P63
(Figure 5f‐h). As we observed in repopulated human lung with iPSC‐
epithelial progenitor cells, the cell attachments were not site specific.
The majority of cells within the matrix expressed proliferating cell
nuclear antigen, while few of them displayed caspase‐3, indicating cells
were able to proliferate in the acellular rat matrix (Figure 5i,j). The qRT‐
PCR revealed the pronounced expression of different alveolar (SPC
and NKX2.1) and airway epithelial (P63, CK5, CCSP, and Mucin5AC)
markers in the engineered rat lung compared with the same cells
grown on tissue culture plate, indicating the natural scaffold and co‐
culture with endothelial cells may have improved the expression of
epithelial cell markers (Figure 5m). However, the differences in gene
expression level were not significant for most of epithelial markers,
except for the P63 gene.
In the vascular compartment, rat microvascular endothelial cells
repopulated the vascular matrix and expressed several functional
markers. Immunofluorescence staining for markers CD31 and
endothelial nitric oxide synthase (eNOS) showed extensive expression
of these markers in repopulated rat lungs (that also contained epithelial
cells; Figure 5k,l). By qPCR, engineered lungs containing RLMEC also
expressed pronounced levels of eNOS, CD31, and CD144 in
engineered rat lung. We observed a high level of eNOS in engineered
rat lung, which is important for endothelial cell function and inhibition
of intravascular coagulation (Figure 5m).3.4 | Assessment of cellular response to different
acellular lung scaffolds
As part of our post‐production assessment, we compared the
expression levels of several lung epithelial markers in iPSC‐derived
progenitor cells when seeded into decellularized human and rat
lung scaffolds. Comparison of the engineered rat lung with
engineered human lung for attachment of cells showed that the










FIGURE 3 Functional culture of engineered human lung made of human lung scaffold and iPSC‐derived lung epithelial progenitor cells in a
bioreactor system. (a) Recellularized human lung scaffold with iPSC‐lung epithelial progenitor cells in a bioreactor culture system. (b‐c)
Representative images of haematoxylin and eosin sections of recellularized human lung after 4 days of culture. (d‐e) Haematoxylin and eosin images
of a native human lung (scale bar = 100 μm applies to panels b‐e). (f‐q) Immunofluorescent images of recellularized lung tissue at day 4 for (f‐h) 4′,6‐
diamidino‐2‐phenylindole (DAPI) and NKX2.1, (i‐k) DAPI and surfactant protein C (SPC), (l‐n) DAPI and Forkhead box protein J1 (FOXJ1), and (o‐q)
DAPI and Clara cell secretory protein (CCSP; scale bar = 63 μm applies to all panels f‐q; arrows show the cells landed in airway express FOXJ1 and
CCSP)
GHAEDI ET AL. e1629similar to human lung tissue. Averaged data for expression of sev-
eral lung markers indicated a similar level of gene expression for
P63, CCSP, and Mucin 5 AC in iPSC‐derived lung progenitor cells
that were cultured on rat or human lung scaffolds (Figure 6a‐h).Indeed, there were no significant differences in expression levels
of lung markers in iPSC‐derived lung progenitor cells cultured on
the human matrix as compared with cells cultured in rat lung scaf-




FIGURE 4 Proliferation and gene expression of induced pluripotent stem cell (iPSC)‐derived progenitor cells in repopulated human lung matrix. (a)
Immunostaining for proliferating cell nuclear antigen (PCNA; red), caspase (green), and 4′,6‐diamidino‐2‐phenylindole (DAPI) in an engineered
human lung at day 4 (scale bar = 40 μm) and (b) quantification of percentage of PCNA+ nuclei (y axis, percentage proliferation based on the number
of positive nuclei stained for PCNA compared with total cell numbers in three high power fields). (c) Quantitative reverse transcription‐PCR analysis
of epithelial markers in recellularized lung tissue with iPSC‐lung progenitor cells following 4 days of culture. The expression of lung alveolar and
airway epithelial cell markers are normalized to glyceraldehyde‐3‐phosphate dehydrogenase levels, and relative expression of each gene was
calculated to normal human lung tissue. (n = 3 tissue samples analysed/lung for quantitative reverse transcription‐PCR and error bars
indicate ± SEM, *indicates p < .05 and ns indicates no significant difference). CCSP = Clara cell secretory protein; FOXJ1 = Forkhead box protein J1;
PCNA = proliferating cell nuclear antigen; SPC = surfactant protein C
e1630 GHAEDI ET AL.4 | DISCUSSION
A key challenge in producing human‐sized engineered lung tissues is to
reliably generate large quantities of epithelial and endothelial cells for
the redistribution to their original locations in the organ (Petersen,
Calle, & Niklason, 2011; Rackley & Stripp, 2012). In effort to address
this limitation, we developed a method for differentiation of iPSCs
to alveolar‐like and conducting airway epithelial‐like cells, at scale(Ghaedi et al., 2013; Huang et al., 2013; Ott & Mathisen, 2011;
Weiss et al., 2013).
The embryonic respiratory system originates from the DE
(Mou et al., 2012; Rackley & Stripp, 2012) and differentiates into many
kinds of specialized lung epithelial cells. Using our previous protocol,
we were able to generate more than 85% endodermal cells from
human iPSCs by exposing them to saturating concentrations of activin







FIGURE 5 Characterization of engineered rat lung from human iPSC‐lung epithelial progenitor cells cultured in the rat bioreactor system. (a‐b)
Representative H&E staining of engineered rat lung after 4 days of culture (scale bar = 200 μm for a‐b panels). (c‐l) Immunofluorescence
analysis of human lung epithelial cell markers and rat endothelial cell markers in an engineered rat lung at day 4 of culture. (c) surfactant protein C
(SPC), (d) surfactant protein B (SPB), (e) NKX2.1, (f) Clara cell secretory protein (CCSP), (g) Forkhead box protein J1 (FOXJ1), (h) P63, (i) proliferating
cell nuclear antigen (PCNA), (j) caspase (scale bar = 31 μm applies to all panels except panel l), (k) endothelial nitric oxide synthase (eNOS), and (l)
CD31 (scale bar = 21 μm). (m) Quantitative reverse transcription‐PCR analysis of human lung alveolar (NKX2.1 and SPC) and airway (P63, CK5,
CCSP, and Mucin 5 AC) epithelial markers and of rat endothelial cell markers (eNOS, CD31, and CD144) at day 4 of culture. The Ct values of each
gene were normalized to glyceraldehyde‐3‐phosphate dehydrogenase, and the relative expression of each gene was calculated to the human or rat
lung tissue control. (All error bars represent ± SEM. *indicates p < .05 and ns indicates no significant difference)








FIGURE 6 Assessment of expression of lung epithelial markers in rat and human lung scaffolds. (a‐c) Quantitative reverse transcription‐PCR
analysis of human lung alveolar epithelial markers (a) surfactant protein C (SPC), (b) NKX2.1, (c) T1α, and (d‐h) human lung airway epithelial
markers (d) CK5, (e)P63, (f) Forkhead box protein J1 (FOXJ1), (g) Mucin 5 AC, and (h) Clara cell secretory protein (CCSP) in iPSC‐derived lung
progenitor cells, cultured into the decellularized rat and human lung scaffold compared with native human lung. The expression of each lung
epithelial marker was normalized to glyceraldehyde‐3‐phosphate dehydrogenase levels and relative gene expression to normal human lung tissue
were calculated for each gene. (n = 3 of iPSC‐lung cell samples before seeding, engineered rat and human lung samples were analysed. Error bars
represent the ±SEM, *indicates p < .05 and ns indicates no significant difference)
e1632 GHAEDI ET AL.the DE folds to form the gut tube and is patterned along the anterior–
posterior and dorsal–ventral axes (Zorn & Wells, 2009). Paracrine sig-
nals from the surrounding tissues result in specification of the lung
field in the ventral AFE, which can be first identified by expression of
the transcription factor NKX2.1 (Green et al., 2011; Longmire et al.,
2012). Therefore, in the second step, we sought to differentiate the
DE further to AFE by dual inhibition of TGF‐β/BMP andWnt signalling
in iPSC‐derived DE (Green et al., 2011; Longmire et al., 2012). Then, to
specify lung cell fate and generate NKX2.1 cells, we exposed cells to
the combination of bFGF, BMP4, CHIR (Wnt signalling), and KGF.The choice of growth factor combination was driven from previous
findings (Ghaedi et al., 2013; Huang et al., 2014; Longmire et al.,
2012; Mou et al., 2012), which showed that the FGF and BMP4 family
members KGF and WNT3a are implicated in providing signals during
embryogenesis for patterning into lung endoderm.
The human lung features major differences in the composition of
the epithelium along its proximodistal axis. The luminal epithelium of
trachea, bronchi, and bronchioles is largely composed of ciliated, basal,
and Clara‐like (or Club) cells. The most distal region of the lung is
organized into a complex system of alveoli that are comprised of type
GHAEDI ET AL. e1633II and type I epithelial cells (Ali et al., 2002; Garcia et al., 2012;
Hashimoto et al., 2012; Rawlins & Hogan, 2006). Early lung endoderm
cells (NKX2.1+) are multipotent, and their fate is dependent upon sig-
nals that control proximal versus distal cell fates.
To differentiate the early lung progenitor cells into the type II pro-
genitor cells, we cultured the progenitor cells in differentiation media
containing KGF, FGF10, RA, CHIR, and EGF for another 15 days after
which CHIR was removed from the differentiation cocktail for the rest
of differentiation. To enhance the differentiation of NKX2.1+ progeni-
tors into airway progenitor cells, the growth factor combination in
induction medium was switched to BMP7, KGF, a high concentration
of retinoic acid. We found low WNT signalling pathway along with
high RA and BMP7 augmented the airway progenitor cells. Together,
our data show that using our modified conditions for human type II
and airway differentiation, we successfully converted the AFE cells
into type II and airway epithelial progenitor cells with good efficiency.
Quantitative RT‐PCR also confirmed that these iPSC‐derived epithe-
lial‐like cells were capable of proliferating for several passages (up to
P4), and we generated tens of millions of cells with which to seed acel-
lular human matrix scaffolds in this report. However, the differentiated
cells at this stage were still multipotent stem cells, and therefore, these
cells were the ideal cells for reseeding the airway structures in
decellularized human lung scaffolds.
In the acellular human scaffolds, the iPSC‐derived progenitor cells
repopulated the scaffold in both airways and the alveolar compartment,
forming a repopulated tissue that resembled, to some degree, human
lung ex vivo, in a bioreactor system. In this study, we were also able to
demonstrate the feasibility of producing an engineered rat lung contain-
ing human iPSC‐derived epithelial progenitors and rat lung microvascu-
lar endothelial cells. In the rat scaffold, progenitor cells derived from
iPSC were distributed from airway to alveoli, and these engineered
lungs displayed much of the microarchitecture of native rat lung.
In the previous report (Gilpin et al), rat lung matrices were
repopulated with early lung progenitor cells that were specified to
anterior foregut but which displayed very few markers of differenti-
ated lung epithelium (Gilpin et al., 2014). In this current report, we
repopulate both human and rat lung tissues using iPSC‐derived epithe-
lial progenitors. In contrast to the previous report, in this study, we
engineered human lung tissues using two types of iPSC‐derived epi-
thelial progenitor cells, including type II‐like progenitor cells and airway
basal‐like cells.
Although these results are encouraging, multiple issues remain to
be addressed. For example, to reliably generate large quantities of
well‐differentiated epithelial cells from iPSCs, the differentiation
protocol must be further improved. In future studies, we will test the
addition of other combinations of growth factors on the improvement
of the differentiation and maturation of iPSC‐derived cells.
Differentiation of iPSC cells on soft substrates as well as applying
mechanical cell stretching during directed differentiation may
improve cell growth and epithelial phenotype. In addition, cell
differentiation and ciliation may be improved in air‐liquid interface
during whole‐lung culture.
Moreover, the use of stem or progenitor cells for recellularization
requires long‐term in vitro culturing for cellular proliferation, matura-
tion, and attachment, which must be standardized in the future andalso be made affordable. Moving forward, one of the next challenges
in lung tissue engineering is the creation of an engineered lung tissue
that is functional after implantation in vivo. For successful long‐term
gas exchange, a formation of good barrier function in the engineered
lung is required. The integrity of the physical barrier function in the
lung is provided by epithelial and endothelial cells that are mature
and express the adhesive molecules to form tight intercellular junc-
tions. Improved strategies for generating more mature vascular endo-
thelium and epithelium, so as to better maintain barrier function and
decrease propensity for bleeding and vascular leak, are necessary. Suf-
ficient secretion of surfactants is also required for lung function, to
prevent alveolar collapse and preserve bronchiolar patency. Produc-
tion of surfactant by fully differentiated type II alveolar cells would
enable lung inflation without exogenous surfactant.
Considering the potential, distant future clinical application of
engineered lungs, other critical issues such as anticoagulation, endothe-
lialization with patient specific endothelial cells, and potential immuno-
genicity of lung matrix, need to be resolved. To advance these various
areas, in vitro, and in vivowork in large and small animalmodelswill con-
tinue to be required. But beyond the application of natural scaffolds and
stem cells in tissue engineering, these ex vivo culture systems will facil-
itate studies of both basic pathology and lung development and will
assist the development of novel therapies going forward.
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